tiuaematter (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . A growing body of data has revealed that many CP-PAHs are mutagens and animal carcinogens and thus do~potentially pose a significant health threat to humans (2, (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) Figure 1 .
We identified 1C10 isomers in combustion samples by GC/MS and HPLC with diode-array spectrophotometric detection.
Results are presented for fuel-rich ethylene combustion products from a jetstirred/plug-flow reactor. The four C H PAH isomers were tested for mutagenicity in a forward mutation assay based on Salmonella typhimurium. They were also tested for mutagenic activity in human cells.
Methods
The jet-stirred/plug-flow combustor was designed to provide well-defined combustion conditions, and its use is part of an ongoing program aimed at understanding and controlling the combustion chemistry responsible for mutagen formation. Fuel-rich combustion in a jet-stirred reactor (fuel equivalence ratio, 2.37, C/O, 0.79 1) provides baseline input to a close-coupled, plug-flow reactor where continuing molecular-weight growth reactions occur. Detailed descriptions of this combustor are available elsewhere (23) (24) (25) .
In this study, the fuel was ethylene ( 
Mutagenicity Assays
The samples, dissolved in dichloromethane, were prepared for bioassay by adding a measured amount of dimethyl sulfoxide in a V-bottom vial. We evaporated the dichloromethane with a gentle stream of nitrogen until the total volume was reduced to that of the original dimethyl sulfoxide. Sample concentrations in dimethyl sulfoxide were typically 10-20 mg/ml.
We used the forward mutation assay to 8-azaguanine resistance in S. typhimurium strain TM677 to measure bacterial mutagenicity. Detailed protocols for measuring forward mutation have been described previously (27) (28) (29) . Briefly, we suspended exponentially growing bacteria in medium in the presence of test sample for 2 hr. Samples at a number of concentrations ranging from 0.10 to 20 pg/ml, depending on their mutagenic potency, were exposed to the bacteria in the presence of 5% (v/v) Aroclor-induced post-mitochondrial supernatant (PMS). Cultures containing PMS had an NADPH-generating system. After 2 hr we resuspended cells in fresh medium. Aliquots were plated in the presence or absence of the selective agent (8-azaguanine, 50 pg/ml). We performed each assay in duplicate with triplicate plates for each experiment. We counted colonies at 48 hr and determined the mutant fraction (MF) as the number of colonies formed under selective conditions divided by the number of colonies formed under nonselective conditions multiplied by the dilution factor. The assay was ruled positive if at any sample concentration: 1) the number of mutant colonies in the treated cultures was greater than the number of mutant colonies in the control cultures with greater than 99% confidence as calculated by Poisson distribution, and 2) the MF exceeded the 95% upper confidence limit for the cumulative historical control (14 x 10o-5).
We tested compounds for mutagenic activity at the thymidine kinase (tk) locus in MCL-3 cells. These cells were derived from an L3 variant (30) (32) . L3 cells have a 2-fold higher CYPlAI activity and a lower background mutation frequency at the tk locus than AHH-1 cells.
We adapted the assay protocol from the procedure used with AHH-1 cells (33) . Exponentially growing cells were incubated in duplicate cultures (6 AA aceanthrylene current negative control (Dunnet's t test) and must be greater than the 99% upper confidence limit of the historical control observations (35) . We estimated toxicity by cumulative growth of the cell cultures from the beginning of treatment to plating. Relative survival was calculated by dividing the cumulative growth of the sample-treated cultures by the cumulative growth of the negative control cultures.
Synthesis
(In this section, boldface numbers refer to the corresponding compounds in Figure  2 .) CPP was prepared from pyrene according to the method published in the literature (36) . AA and CPAA were both prepared from anthracene by methods we have described (37, 38) . For the synthesis of AP (Fig. 2) , we treated phenanthrene with formaldehyde and hydrochloric acid (36) . This gave a mixture of 1-(chloromethyl)phenanthrene (1) and 9-(chloromethyl)phenanthrene (2) (ratio 1:6). This mixture was treated under phase transfer catalytic conditions with sodium cyanide yielding a mixture of 1-(phenanthrene)acetonitrile (3) and 9-(phenanthrene)acetonitrile (4) . Saponification with KOH in refluxing ethanol afforded the corresponding acetic acid derivatives (5 and 6). Conversion of the acids to their corresponding acid chlorides with oxalyl chloride (37) and subsequent treatment with AlCl3 yielded a mixture of acephenanthren-4-one (7) and acephenanthren-5-one (8) . NaBH4 reduction of the ketones and subsequent dehydration with p-tol-uene sulfonic acid gave AP as yellow plates in 25% overall yield starting from phenanthrene.
For the preparation of CPAP (Fig. 2) , we reduced the mixture of 7 and 8 under Wolff-Kishner conditions to yield acephenanthrene (9 (2) . Phen- anthrene was chloromethylated according to the procedure of Fernandez et al. (39) . After work-up we purified the crude product by flash chromatography over a short column of silica. This procedure was sufficient to remove slow-running degradation components and to obtain the reaction products sufficiently pure for the next reaction step. IH-NMR revealed, next to 9-(chloromethyl)phenanthrene (2) , some 1-(chloromethyl)phenanthrene (1) 1-(Phenanthrene)acetonitrile (3) and9-(Phenanthrene)acetonitrile (4) . A mixture of 1 and 2 (21.7 g, 95 mmol), NaCN (7.5 g, 153 mmol) and triethylbenzylammonium chloride (3.2 g, 14.5 mmol) was suspended in a mixture of CH2Cl2 (30 ml) and H20 (6 Acephenanthren-4-one (7) andAcephenanthren-5-one (8 
Results and Discussion
Bacterial Mutagenicity Assay
The four C18H,O isomers were tested in a forward mutation assay based on S. typhimurium as described in Methods. Additional details concerning this assay have Volume 101, Number 2, June 1993been published elsewhere (28, 29) . All isomers were tested in the presence of an exogenous metabolizing enzyme system (PMS). Such enzyme mixtures are generally required to obtain a mutagenic result for PAHs with bacterial assays.
The results for two C18HHo isomers are shown in Figure 3a by survival values near 100%. Mutagenicity results for CPAP and CPAA are shown in Figure 4 . As illustrated in Figure 4a , CPAA is the most potent bacterial mutagen of the four C18H0o isomers tested and is approximately three times as mutagenic as BaP in this assay. CPAP, although yielding statistically significant mutagenicity results, is relatively inactive compared with BaP.
Bacterial mutagenicity results for CPAA and CPAP were compared with those of their monocyclopenta-fused analogs, AA and AP. In Figure 4a and b, results for CPAA are compared with those for AA; in Figure 4c and 4d, results for CPAP are compared with those for AP. Although results for CPAP and AP were similar, the mutagenic activity of CPAA was an order of magnitude greater than that of AA. When comparing results for CPAA and AA, it should be noted that horizontal scale (dose) values are roughly an order of magnitude lower for CPAA (0-5 gg/mL) than for AA (0-40 pg/ml).
CPAA is one of the most potent bacterial mutagens tested to date in our forward mutation assay.
Human Cell Mutagenicity Assay
In addition to the bacterial assay, the compounds were also tested for mutagenic activity at the tk locus in MCL-3 cells. Results for BF, CPP, and BaP are shown in Figure 5a , b and c, respectively. For this assay, error bars reflect 1 SD from the mean value. Mutagenicity values on the vertical axes are in units of 1 x 10-6 mutant fraction or parts per million. As shown in Figure 5 , BaP is a very potent mutagen in this assay, showing statistically significant mutagenic activity below 0.5 pg/ml. CPP is also an important human cell mutagen, but it is less active than BaP in this assay.
In contrast, BF (Fig. 5a ) is inactive in this human cell assay but quite active in bacteria as shown earlier (Fig. 3a) . It should be noted that the BF analogs fluoranthene, benzo[b]fluoranthene, benzoj]fluoranthene, and benzo[k]fluoranthene (each has an internal cyclopenta-fused ring) are also inactive in the MCL-3 assay. Fluoranthene, however, is active in our bacterial assay (22' ). Presumably, the MCL-3 line of human cells lacks the enzyme(s) necessary for metabolic activation of fluoranthene-based PAHs.
Human cell mutagenicity results for CPAA and CPAP were compared with those of their monocyclopenta-fused analogs AA and AP. Results for CPAA compared with those of AA are shown in Figure 6a and b, respectively, and results for CPAP compared with those of AP are shown in Figure 6c and d, respectively. Comparing the results for CPAP and AP, it is seen that both PAHs are negative in this assay. On the other hand, both CPAA and AA are mutagenic. When comparing results for CPAA and AA, it should be noted that the horizontal scale (dose) is a factor of 10 150 ri (0.0-0.9 pg/ml) than for AA (0-9 pg/ml).
Comparing the data in Figure 6a and b, it is seen that the human cell mutagenicity of CPAA is more than an order of magnitude greater than that of AA. Considering both the bacterial and human cell data, it can be hypothesized that the addition of peripherally fused cyclopenta groups to anthracene-based molecules will have a significant biological effect, but the addition of the same groups to phenanthrene-based structures will have little effect. No adequate explanation of the differences in the mutagenicity of these cyclopenta-fused PAHs can be offered until more information becomes available on the metabolism of these unique compounds.
Chemical Identification
Identification of C18H1o PAH isomers in complex mixtures is hampered by a number of technical difficulties; however, the (23) (24) (25) . Figure 7 shows a portion of an HPLC/ DAD total-absorbance chromatogram obtained for an ethylene combustion sample from the combustor. Conditions are given in the Methods. The wide-band absorbance (236-500 nm) in absorbance units is plotted against the elution volume in milliliters. For PAHs, the wide-band absorbance is roughly proportional to mass (27) . In Figure 7 , the major peak, centered at 25 Figure 7 are those of AP, fluoranthene, and pyrene.
Because our combustion conditions do not promote the formation of C1 8Hl 2 PAHs (e.g., chrysene, benz[a]anthracene) or other interfering species, the HPLC chromatogram appears quite simple. However, when an HPLC fraction containing C18H1o PAH isomers was collected and analyzed by GC/MS, the additional resolution provided by a capillary GC column revealed a more complex picture. Figure 8 shows the C18H1o mass chromatogram (m/e 226) for another ethylene combustion sample taken from our jetstirred/plug flow combustor. The three C18HIo isomers (CPP, BF, CPAP) that were incompletely resolved by HPLC (Fig.  7) are better resolved by capillary gas chromatography. Moreover, at increased resolution, the presence of additional isomers is revealed. A number of other C18H1o isomers, identified through their mass spectra, were also found in the sample. They are indicated by peaks a-h in Figure 8 . One of these additional isomers is likely to be cyclopenta[ca fluoranthene. Other C1 8H lo PAHs can be formed in the combustor through the addition of an acetylene group to a C16H10 PAH (e.g., fluoranthene, pyrene). Evidence for the possible existence of these types of structures is provided by the presence in the sample of phenyl acetylene, 2-ethynyl naphthalene, and a number of ethynyl acenaphthylenes (4, 5) .
Also seen in Figure 8 are some other components eluting close to the C18H0o
PAHs, and they are labeled with their molecular ion values obtained from their mass spectra. The small peak labeled 228 is a C18H12 isomer; the one labeled 240 gave a mass spectrum consistent with a C18H12 species incorporating an added methylene bridge. The 214 peak is thought to be a methylene-bridged acephenanthrylene.
Summary
In a forward mutation assay using on S. typhimurium, CPP, BF, and CPAA were roughly twice as potent as BaP, whereas CPAP was only slightly active. In a human cell mutagenicity assay usinF MCL-3 cells, a derivative of AHH-1 TK+ cells containing higher native P450 lAl activity, CPP and CPAA were strongly mutagenic but less active than BaP, while CPAP and BF were inactive at the dose levels tested. Bacterial and human cell mutagenicity results for CPAA and CPAP were compared with those of their monocyclopentafused analogs AA and acephenanthrylene AP. Mutagenicity results for both human cells and bacteria showed that the mutagenic activity of CPAP generally approximated that of AP: Both were inactive in human cells and weakly mutagenic in bacteria. In contrast, the mutagenic activity of CPAA was roughly an order of magnitude greater than that of AA in both assays. Results of chemical analyses showed that C18H1o CP-PAHs were abundant in every combustion and pyrolysis sample tested. Generally, CPP was the most abundant and the most frequently occurring C18HHo isomer, whereas CPAP was equally common but present but at lower levels. BF was also found in a number of samples, whereas CPAA was undetected.
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